bluebird bio completes restated 10-K, delays 2024 Q2 10-Q
https://seekingalpha.com/news/4149749-bluebird-bio-completes-restated-10-k-delays-2024-q2-10-q?source=feed_sector_healthcare
Sep 13, 2024 - bluebird bio has completed restating its financial reports for 2022 and part of 2023, filing its 10-K for 2023 and Q1 10-Q for 2024. Read more here.
0
Bicara, MBX Bio lead gainers as biotech trio makes trading debut
https://seekingalpha.com/news/4149681-bicara-mbx-bio-lead-gainers-among-biotech-ipos?source=feed_sector_healthcare
Sep 13, 2024 - Bicara Therapeutics (BCAX), MBX Biosciences (MBX) and Zenas BioPharma (ZBIO) make trading debuts with upsized offerings, implying biotech IPO resurgence. Read more here.
0
INmune Bio stock dips on $13M securities offering
https://seekingalpha.com/news/4149444-inmune-bio-stock-dips-on-13m-securities-offering?source=feed_sector_healthcare
Sep 13, 2024 - INmune Bio (INMB) shares dropped 14% after launching a $13M securities offering.
0
Adicet Bio narrows focus on lead asset (update)
https://seekingalpha.com/news/4148700-adicet-bio-stock-slips-new-strategic-focus?source=feed_sector_healthcare
Sep 11, 2024 - Adicet Bio (ACET) stock slips as company reallocates resources to focus its lead asset on ADI-001 for autoimmune conditions. Read more here.
0
Telesis Bio Seeks Delisting From Nasdaq ; Stock Down 57% In Pre-market
https://www.rttnews.com/story.aspx?Id=3474448
Sep 11, 2024 - Telesis Bio Inc. (TBIO) Wednesday announced its decision to delist the company's shares from the Nasdaq Global Select Market, as it failed to meet compliance with the stockholders' equity requirement for continued listing. The stock was down more than 57 percent in pre-market to $1.60.
0
Telesis Bio to delist its securities from Nasdaq
https://seekingalpha.com/news/4148500-telesis-bio-to-delist-its-securities-from-nasdaq?source=feed_sector_healthcare
Sep 10, 2024 - Telesis Bio (TBIO) plans to delist from Nasdaq due to non-compliance with stockholder's equity requirement.
0
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
https://www.zacks.com/stock/news/2333922/after-plunging-5-53-in-4-weeks-here-s-why-the-trend-might-reverse-for-kronos-bio-kron?cid=CS-ZC-FT-tale_of_the_tape|rsi-2333922
Sep 10, 2024 - The heavy selling pressure might have exhausted for Kronos Bio (KRON) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
0
Intelligent Bio Solutions stock rallies on reporting Q4 revenue of $0.73M, up 64% Y/Y
https://seekingalpha.com/news/4147990-intelligent-bio-solutions-stock-rallies-on-reporting-q4-revenue-of-073m-up-64-yy?source=feed_sector_healthcare
Sep 09, 2024 - Intelligent Bio Solutions (INBS) reports strong revenue growth for Q4 and FY 2024, attributing it to market demand and customer base expansion.
0
Vor Bio stock rallies post-market on trem-cel study data
https://seekingalpha.com/news/4147513-vor-bio-stock-rallies-post-market-on-trem-cel-study-data?source=feed_sector_healthcare
Sep 05, 2024 - Vor Bio (VOR) stock rallied 64% post-market after the company reported positive data for its gene-edited stem cell therapy trem-cel in the treatment of AML. Read more here.
0
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
https://www.zacks.com/stock/news/2331551/theravance-bio-tbph-up-2-2-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2331551
Sep 04, 2024 - Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0